關(guān)鍵詞

帕博西尼 細(xì)胞毒性 奧貝利單抗 阿伐可泮 達(dá)雷妥尤單抗 阿替利珠單抗 貝伐珠單抗 替雷利珠單抗 戈利昔替尼 潘瑞魯單抗

#今日行業(yè)熱點(diǎn)#

①The Lancet Oncology：Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study

臨床試驗(yàn)：帕博西尼（palbociclib）聯(lián)合giredestrant或阿那曲唑（Anastrozole）輔助用于雌激素受體陽(yáng)性、her2陰性早期乳腺癌(coopERA乳腺癌)的一項(xiàng)開(kāi)放標(biāo)簽、隨機(jī)、對(duì)照、Ⅱ期研究

DOI: 10.1016/S1470-2045(23)00268-1

②The Lancet Oncology：Combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: a phase 1, first-in-human trial

臨床試驗(yàn)：聯(lián)合細(xì)胞毒性和免疫刺激基因療法用于原發(fā)性成人高級(jí)別膠質(zhì)瘤:一項(xiàng)Ⅰ期、首次人體試驗(yàn)

DOI: 10.1016/S1470-2045(23)00347-9

③The Lancet Rheumatology：Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trial

臨床試驗(yàn)：奧貝利單抗 (Obexelimab)用于IgG4相關(guān)疾病患者的安全性、有效性和作用機(jī)制:一項(xiàng)開(kāi)放標(biāo)簽、單臂、單中心、Ⅱ期試點(diǎn)試驗(yàn)

DOI: 10.1016/S2665-9913(23)00157-1

④The Lancet Rheumatology：The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial

臨床分析：阿伐可泮（avacopan）用于抗中性粒細(xì)胞細(xì)胞質(zhì)抗體(ANCA)相關(guān)血管炎患者健康相關(guān)生活質(zhì)量的影響:對(duì)ADVOCATE試驗(yàn)數(shù)據(jù)的分析

DOI: 10.1016/S2665-9913(23)00092-9

⑤EClinicalMedicine：Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trial

臨床試驗(yàn)：伊沙佐米（Ixazomib）、達(dá)雷妥尤單抗（Daratumumab）和低劑量地塞米松（Dexamethasone）用于新診斷多發(fā)性骨髓瘤的中等適應(yīng)度患者:一項(xiàng)開(kāi)放標(biāo)簽Ⅱ期試驗(yàn)

DOI: 10.1016/j.eclinm.2023.102167

⑥EClinicalMedicine：Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis

臨床分析：阿替利珠單抗（Atezolizumab）聯(lián)合貝伐珠單抗（Bevacizumab）用于不可切除肝細(xì)胞癌的有效性和安全性:一項(xiàng)系統(tǒng)評(píng)價(jià)和薈萃分析

DOI: 10.1016/j.eclinm.2023.102179

⑦PD-1抗體替雷利珠單抗的新適應(yīng)癥上市申請(qǐng)獲CDE受理，推測(cè)申報(bào)的適應(yīng)癥為廣泛期小細(xì)胞肺癌（ES-SCLC）

⑧高選擇性JAK1抑制劑戈利昔替尼擬納入優(yōu)先審評(píng)，用于復(fù)發(fā)或難治的外周T細(xì)胞淋巴瘤（r/r PTCL）

⑨脂蛋白（a）-Lp（a）抑制劑莫伐倍林（Muvalaplin）首次人體Ⅰ期臨床積極結(jié)果公布，24小時(shí)內(nèi)顯著降低膽固醇

⑩靶向CTGF的IgG1亞型全人源抗體潘瑞魯單抗（Pamrevlumab）用于杜氏肌營(yíng)養(yǎng)不良癥(DMD)的Ⅲ期臨床未達(dá)到主要終點(diǎn)和關(guān)鍵次要終點(diǎn)

科學(xué)探索的世界充滿挑戰(zhàn)，AtaGenix致敬每一位拓荒者，更致力于成為您信賴的合作伙伴！